Cetuximab Reduces Locoregional Failure in Anal Canal Carcinoma, Adds Toxicity

Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity.

Source: CancerNetwork - January 11, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Source Type: news